KIT Mutation-NTRK fusion oncogenic driver switch: a novel mechanism of acquired imatinib resistance in GIST [PDF]
Imatinib is the first-line treatment for advanced gastrointestinal stromal tumors (GISTs) harboring KIT or PDGFRA mutations. Unfortunately, resistance invariably develops, typically through secondary KIT/PDGFRA mutations.
Simona Gloazzo +12 more
doaj +3 more sources
Nestin promotes imatinib resistance in gastrointestinal stromal tumors by enhancing PINK1-dependent mitophagy [PDF]
Background Gastrointestinal stromal tumors (GIST) frequently develop secondary resistance to imatinib, which represents a major obstacle to achieving durable clinical benefit. However, the molecular mechanisms underlying acquired resistance remain poorly
Yuehan Yin +8 more
doaj +2 more sources
The effect of ubiquitination and deubiquitination to imatinib resistance in gastrointestinal stromal tumors [PDF]
Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor. Imatinib, as a receptor-type tyrosine kinase inhibitor (TKI), becomes a first-line drug for adjuvant therapy and prognosis.
Huade Huo +10 more
doaj +2 more sources
Targeting the insulin-like growth factor-1 receptor to overcome imatinib resistance in chronic myeloid leukemia [PDF]
Patients with chronic myeloid leukemia (CML) frequently develop resistance to tyrosine kinase inhibitors such as imatinib. In this study, we explored the role of the insulin-like growth factor 1 (IGF-1) signaling pathway in CML and imatinib resistance ...
Seiichi Okabe, Yuya Arai, Akihiko Gotoh
doaj +2 more sources
RP11-616M22.7 recapitulates imatinib resistance in gastrointestinal stromal tumor [PDF]
Emerging evidence has shown that long non-coding RNAs (lncRNAs) play crucial roles in human cancers. However, systematic characterization of lncRNAs and their roles in gastrointestinal stromal tumor (GIST) therapy have been lacking.
Yebo Shao +9 more
doaj +2 more sources
Meta‐Analysis of Imatinib Resistance in Chronic Myeloid Leukemia due to BIM Gene Deletion and Single Nucleotide Polymorphisms Reveals Ethnic Variations in Prevalence [PDF]
Background and Aim Deletion and single nucleotide polymorphisms in the BIM gene have been proposed as a potential contributor of intrinsic resistance to imatinib in patients with chronic myeloid leukemia (CML).
Abhinav Bhattarai +4 more
doaj +2 more sources
Targeting Integrin α2 to Overcome Imatinib Resistance in Chronic Myeloid Leukemia Cells [PDF]
Chronic myeloid leukemia (CML) is a blood disorder caused by a genetic alteration that creates the BCR-ABL fusion gene, leading to continuous activation of cell growth signals and uncontrolled proliferation of the blood cells.
Yalda Hekmatshoar +7 more
doaj +2 more sources
LncRNA IRAIN overcomes imatinib resistance in chronic myeloid leukemia via NF-κB/CD44 pathway inhibition [PDF]
Summary: The development of tyrosine kinase inhibitors (TKIs) has revolutionarily increased the overall survival of patients with chronic myeloid leukemia (CML). However, drug resistance remains a major obstacle.
Xijia Wang +11 more
doaj +2 more sources
Small RNA activation of CDH13 expression overcome BCR-ABL1-independent imatinib-resistance and their signaling pathway studies in chronic myeloid leukemia [PDF]
BCR-ABL1-independent resistance to imatinib has no effective treatment due to its complexity and diversity. We previously reported that the CDH13 oncogene was expressed at low levels in BCR-ABL1-independent resistant CML cell lines.
Rui Su +7 more
doaj +2 more sources
Deciphering the tumor immune microenvironment of imatinib-resistance in advanced gastrointestinal stromal tumors at single-cell resolution [PDF]
The heterogeneous nature of tumors presents a considerable obstacle in addressing imatinib resistance in advanced cases of gastrointestinal stromal tumors (GIST). To address this issue, we conducted single-cell RNA-sequencing in primary tumors as well as
Xuechao Liu +11 more
doaj +2 more sources

